



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: ) Attorney Docket No.  
Timo Kars van den Berg et al. ) 080743235001  
)  
Serial No.: 10/007,275 )  
)  
Filed: October 26, 2001 )  
)  
For: METHOD FOR INHIBITING CELL )  
FUNCTIONING FOR USE IN ANTI- )  
INFLAMMATORY AND ANTI- )  
TUMOR THERAPIES )  
)  
Examiner: Yaen, Christopher H. )  
)  
Group Art Unit: 1642 )  
)  
Confirmation No.: 5284 )

RECEIVED  
JUL 07 2003  
TECH CENTER 1600/2900

AMENDMENTS TO THE SPECIFICATION

Amend paragraph 0027 to read as follows:

*AI*  
The rat macrophage cell line NR8383 (Adams et al. 1998) are cultured at a density of 0.25 x 10<sup>6</sup> cells/ml in a 96-well cell culture plate in RPMI-1640 medium containing 2% fetal calf serum and 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. This is performed in the presence (or absence) of anti-SIRP Fab-fragments (ED9 or ED17; 40 µg/ml) or control Fab-fragments (OX41; 40 µg/ml). After 24 h <sup>3</sup>H-thymidine (1 µCi/well) is added and the cells are incubated for another 6 hours. The cells are harvested using a cell harvester and cell incorporated radioactivity is determined in a Micro-β-plate reader. The mean results are shown in Table 1 below in Table 1:

Table 1

Treatment	Mean (in c.p.m.)	SD (standard dev.)
control	132783	2730
ED17 Fab	6845	197
OX41 Fab	154889	8528

A1  
Amend paragraph 0029 to read as follows:

A2  
To examine the effects of ED9 or ED17 Fab on myeloid cell division, NR8383 cells are  
assayed as described in the macrophage division test. (Note to Examiner - previous underline is  
in original document and is not part of this amendment.) As illustrated in Table 1 ~~table 1~~, ED 17  
~~ED~~ strongly inhibits division (analyzed by thymidine incorporation), whereas OX41 Fab has  
little effect.